Biogen selects Veeva Vault CRM to unify its commercial operations and speed drug delivery to patients
Executive summary: Biogen has chosen Veeva Vault CRM as its global commercial platform to accelerate drug delivery to patients worldwide. The adoption signals increasing reliance on integrated CRM systems in the pharma sector to enhance commercial efficiency and patient access.
Who is involved: Biogen (the adopter) and Veeva Systems (the provider of Vault CRM).
Likely next: Biogen will begin implementation and rollout of Vault CRM across its global operations, with Veeva supporting the deployment.
Biogen’s decision to adopt Veeva Vault CRM reflects a broader trend among large pharmaceutical firms to consolidate commercial processes on a single, cloud-based platform. The move is intended to streamline evidence generation, improve coordination across global markets, and ultimately reduce the time it takes to bring therapies to patients. While the press release does not disclose financial terms or implementation timelines, the selection places Biogen alongside peers such as Regeneron and Eli Lilly that have recently chosen the same Veeva solution.
Timeline
- — Biogen entscheidet sich für Veeva Vault CRM (PR Newswire)
- — Regeneron entscheidet sich für Veeva Vault CRM (PR Newswire)
- — La solution Veeva Vault CRM a été sélectionnée par Eli Lilly and Company (PR Newswire)
Analysis — what this means
Sectors affected
- pharmaceutical commercial operations
- life sciences CRM software
Historical parallels
- Regeneron's adoption of Veeva Vault CRM (August 25, 2026)
- Eli Lilly's selection of Veeva Vault CRM (August 11, 2026)
Key entities
Sources
- Biogen entscheidet sich für Veeva Vault CRM — PR Newswire
- Regeneron entscheidet sich für Veeva Vault CRM — PR Newswire
- La solution Veeva Vault CRM a été sélectionnée par Eli Lilly and Company — PR Newswire